-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, the NMPA official website announced that the marketing application for larotrectinib (larotrectinib sulfate capsules) submitted by Bayer has been approved for the treatment of adult and pediatric patients with solid tumors carrying the NTRK fusion gene
According to public information, larotrectinib is an "unlimited cancer" therapy, and it is the world's first oral TRK inhibitor designed for patients with NTRK gene fusion cancers
Screenshot source: NMPA official website
The full name of NTRK is neurotrophic factor receptor tyrosine kinase
Larotrectinib is a next-generation, highly specific oral TRK inhibitor originally developed jointly by Bayer and Loxo Oncology (acquired by Eli Lilly and Company), which now owns the global development and commercialization of the drug exclusive rights